These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36918269)

  • 1. Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.
    Choi J
    Gut Liver; 2023 Mar; 17(2):179-180. PubMed ID: 36918269
    [No Abstract]   [Full Text] [Related]  

  • 2. Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers.
    Liang LY; Wong VW; Wong GL; Yip TC
    Clin Mol Hepatol; 2023 Jan; 29(1):113-117. PubMed ID: 36314042
    [No Abstract]   [Full Text] [Related]  

  • 3. Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring.
    Tsai YN; Wu JL; Hsu YC
    Clin Mol Hepatol; 2024 Apr; 30(2):293-296. PubMed ID: 38373419
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting liver metabolism: a pathway to cure hepatitis B virus?
    Ajoyan H; Douglas MW; Tu T
    Expert Rev Gastroenterol Hepatol; 2023; 17(7):645-647. PubMed ID: 37318059
    [No Abstract]   [Full Text] [Related]  

  • 5. Genomics on the road to functional cure of hepatitis B.
    Balagopal A; Thomas DL
    J Hepatol; 2024 Jan; 80(1):6-7. PubMed ID: 37984710
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.
    Liu SY; Yuan C; Tong XM
    J Hepatol; 2022 Nov; 77(5):1471-1472. PubMed ID: 35863489
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?
    Liaw YF; Jeng WJ; Chien RN
    Hepatology; 2024 Mar; 79(3):E97-E98. PubMed ID: 37862454
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?
    Dongelmans EJ; Sonneveld MJ; Janssen HLA
    Hepatology; 2024 Mar; 79(3):E95-E96. PubMed ID: 37862458
    [No Abstract]   [Full Text] [Related]  

  • 9. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look!
    Jindal A
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1885-1886. PubMed ID: 34508869
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis B core-related antigen: Are we near a treatment endpoint?
    Gupta T
    World J Gastroenterol; 2022 Jul; 28(27):3532-3534. PubMed ID: 36158266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 12. [Imperatives to strengthen HBsAg screening and expand antiviral therapy indications on hepatitis B among the general population].
    Chen EQ
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):646-648. PubMed ID: 37400392
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of serum Golgi protein 73 for screening chronic hepatitis B virus infection patients needing antiviral therapy in the community.
    Duan J; Wen X; Wang H; Chen W; Gao P; Yuan Q; Zheng H; Liu Y; Wu J; Wang J; Yao M; Lu F
    Chin Med J (Engl); 2022 Nov; 135(22):2741-2743. PubMed ID: 36574219
    [No Abstract]   [Full Text] [Related]  

  • 14. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance.
    Wu Y; Liu Y; Lu J; Cao Z; Jin Y; Ma L; Geng N; Ren S; Zheng Y; Shen C; Chen X
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):514-516.e2. PubMed ID: 30981007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KASL clinical practice guidelines for management of chronic hepatitis B.
    Korean Association for the Study of the Liver (KASL)
    Clin Mol Hepatol; 2019 Jun; 25(2):93-159. PubMed ID: 31185710
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis B virus - recent therapeutic advances and challenges to cure.
    Mouzannar K; Liang TJ
    J Hepatol; 2020 Sep; 73(3):694-695. PubMed ID: 32682539
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
    Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
    Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Perspectives on Development of Curative Strategies for Chronic Hepatitis B.
    Feld JJ; Lok AS; Zoulim F
    Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2040-2050. PubMed ID: 37080262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies.
    Degasperi E; Anolli MP; Lampertico P
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers.
    Mak LY; Hui RW; Cheung KS; Fung J; Seto WK; Yuen MF
    Expert Opin Drug Discov; 2023 Apr; 18(4):401-416. PubMed ID: 36943183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.